martes, 15 de octubre de 2019

Mean survival gain is a better metric for pricing new cancer drugs - STAT

Mean survival gain is a better metric for pricing new cancer drugs - STAT

Cancer Briefing

Opinion: Accounting for hope: using ‘mean survival gain’ to price new cancer drugs

By ALICE CHEN AND DANA GOLDMAN


ADOBE
Using mean survival gain instead of median survival gain in pricing decisions for new cancer therapies is a better way to account for their value.

No hay comentarios: